Sihuan Pharma, a China Military Spin-out, Sees Ebola Drug NDA by Year-End

In a call with investors, Sihuan Pharma announced its newly acquired Ebola treatment, JK-05, could file for China approval by year-end if the drug is fast-tracked under CFDA green-light rules. The company cited the ten-year-old history of the SARS vaccine as an example of regulatory efficiency. Sihuan acquired the drug from China's Academy of Military Medical Sciences (AMMS). The drug company has close ties with AMMS because it was spun out from AMMS in 2001. More details.... Stock Symbol: (HK: 460) Share this with colleagues: // //